The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

The decline in cancer incidence among men and increase among women has narrowed the male‐to-female cancer incidence rate ratio from a peak of 1.6 in 1992 to 1.1 in 2021. In people aged 50-64 years, ...